PIC/S GMP v17 Cannabis Australia: PE009-17 Transition Guide for TGA-Licensed Manufacturers

PE009-17 took effect on 1 September 2025. If you hold a TGA Licence to Manufacture, your quality system has to demonstrate compliance with the new version, not the old one.

The Therapeutic Goods Administration (TGA) adopts the PIC/S Guide to Good Manufacturing Practice by reference under the Therapeutic Goods Act 1989. Every TGA-licensed cannabis manufacturer in Australia is now obligated to comply with the PIC/S GMP v17 cannabis Australia standard, formally known as PE009-17, which superseded PE009-16 on 1 September 2025. This guide explains what changed, who is affected, what your documentation system needs to look like under v17, and how to run a clean transition without panicking over Annex 1.

For the full Australian compliance picture across the ODC, TGA, and state Poisons authorities, see our Australian cannabis compliance checklist pillar guide.

What Is PIC/S GMP v17 and Why Did Australia Adopt It?

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) publishes a single, harmonised Guide to Good Manufacturing Practice used by more than 50 medicines regulators worldwide. The current version is PE009-17, with all parts (Introduction, Part I, Part II, and the Annexes) published by PIC/S on 21 June 2023. Australia, through the TGA, adopted PE009-17 with an effective date of 1 September 2025 for all medicine manufacturing covered by a TGA Licence to Manufacture.

For Australian medicinal cannabis manufacturers, this matters because the TGA does not write its own GMP code. The TGA adopts PIC/S by reference, then inspects against it. A manufacturer that meets PIC/S GMP v17 satisfies the TGA’s manufacturing principles determination. A manufacturer that does not, fails the inspection. This is a different legal mechanism than Health Canada’s Good Production Practices (Canada’s own published standard) or the United States FDA’s 21 CFR Parts 210 and 211 cGMP regulations (which the FDA writes and enforces directly). The three regimes converge on similar quality principles, but each rests on a different legal instrument, so international audit certificates do not transfer cleanly. Cross-jurisdiction parity exists at the principles level only.

The Guide is structured in four parts:

• Part I covers Basic Requirements for Medicinal Products: quality system, premises, equipment, documentation, production, and quality control. This is the framework most cannabis manufacturers operate under day to day.
• Part II covers Active Pharmaceutical Ingredients. Most Australian cannabis cultivators do not hold an API licence, but extractors producing isolates or distillates for downstream formulation often do.
• Annexes 1 through 20 cover product-class specifics. The two most relevant for cannabis are Annex 7 (Manufacture of Herbal Medicinal Products) and Annex 9 (Manufacture of Liquids, Creams and Ointments).
• Glossary defines the terms used across the Guide.

What Changed from PE009-16 to PE009-17?

The single substantive change in PE009-17 is the revised Annex 1 on Manufacture of Sterile Medicinal Products: the biggest Annex 1 rewrite in a decade. PIC/S aligned the document with the European Medicines Agency’s 2022 Annex 1 revision, importing the Contamination Control Strategy (CCS) concept, Quality Risk Management language, and a sharper focus on barrier technologies.

The rest of the Guide carries forward from PE009-16 with editorial cleanup. There are no new burdens on Part I, no rewrite of the documentation chapter, and no changes to Annex 7 affecting herbal cannabis preparations.

If your facility does not run a sterile fill line, the v17 transition is largely a paperwork update. Your QMS reference documents need to cite PE009-17 rather than PE009-16, your training records need to confirm staff awareness, and your inspection-readiness file needs to evidence the review. The substantive lift is reserved for the small number of Australian manufacturers who produce sterile cannabis injectables for clinical trials or compassionate-access programmes.

Do Non-Sterile Cannabis Producers Have to Comply?

Yes, but the obligation kicks in at a specific point. Growing, cutting, and drying cannabis can be done without a TGA Licence to Manufacture, provided the harvested material is supplied as a starting material to a GMP-licensed facility. First crude extraction may also fall within this exemption depending on how it is characterised. The TGA looks at whether the process transforms the herbal substance into a herbal preparation; once it does, you are in GMP territory.

Most Australian licensed producers operate under two regimes simultaneously. The cultivation arm complies with WHO Good Agricultural and Collection Practices and PIC/S GMP Annex 7 at the field level, with documentation focused on seed source, growing conditions, harvest timing, and post-harvest handling. The manufacturing arm picks up GMP at the point the dried flower enters the extraction, blending, or finished-product packaging workflow. Our GACP cannabis cultivation Australia spoke covers the cultivation-side documentation, and the TGO 93 testing limits spoke covers the batch release testing that sits on top of GMP.

If you grow and supply unprocessed dried flower to a third-party GMP-licensed manufacturer, you do not need a manufacturing licence yourself. If you grow, dry, and then extract or formulate on the same premises, you do. The clearest signal is whether your output has an ARTG entry: if it does, GMP applies to the production step.

What Documentation Does PIC/S GMP v17 Require?

PIC/S GMP Chapter 4 (Documentation) is the heart of the inspection. Every TGA inspector walks the documentation file before they walk the floor. The list below is what an inspector expects to find under v17.

Batch records (primary production evidence)

One batch record per lot, capturing every material added, every operation performed, every in-process check, and every signature. Cannabis batch records typically run 40 to 80 pages for a finished product. Records are signed by the operator, reviewed by a supervisor, and approved by the qualified person before release. Electronic batch records are accepted by the TGA provided they meet PIC/S Annex 11 (Computerised Systems): validated software, audit trails, role-based access, electronic signatures.

Equipment calibration and maintenance logs

Every measurement device used in quality decisions has a calibration record on a master schedule: frequency, last-calibration date, next-due date, certificate. Out-of-tolerance findings trigger a deviation and an impact assessment on every lot produced since the last successful calibration.

Environmental monitoring data

Manufacturing rooms hold defined temperature, relative humidity, and (for cleaner areas) airborne particulate or microbial counts. Monitoring is continuous, data is reviewed weekly, and excursions are formally investigated. The cure-room RH trend is one of the most important pieces of evidence the QAP holds. Our spoke on cannabis microbial testing limits walks through environmental monitoring as an early-warning signal.

Personnel training records

Every operator has a documented training file: GMP awareness, SOP-specific training, on-the-job competency verification, and annual refreshers. The QAP cannot release a lot if any operator has expired or missing training. Missing training is one of the most common observations on Australian GMP inspections.

Deviation and CAPA records

Every deviation is documented within 24 hours, investigated via root cause analysis, and resolved with corrective and preventive actions. CAPA effectiveness is verified by reviewing the next three batches. A facility with zero deviation records on file is hiding deviations, and TGA inspectors know to look for the pattern.

Supplier qualification records

Every raw material, starting material, primary packaging component, and contract service has a qualified supplier file: identity check, quality agreement, certificate of analysis, periodic audit, rejected-lot performance review. The supplier file for dried flower starting material is the most scrutinised record on inspection.

Change control records

Any change to a process, equipment, material specification, facility layout, or documented procedure goes through change control: proposed, impact-assessed, QAP-approved, implemented under plan, reviewed for effectiveness. Informal “tweaks” found on inspection are written observations every time.

Annual self-inspection

A formal self-inspection at least annually, executed by qualified internal auditors against a checklist that mirrors the TGA inspection scope. Findings are classified by criticality and assigned CAPAs with target close-out dates. The TGA inspector reads this file before forming their own opinion.

How Do Australian LPs Transition from PE009-16 to PE009-17?

The transition is a gap analysis followed by document control. Manufacturers catching up now are running the same workflow on a tighter clock. The conventional approach Australian quality teams use is:

1. Acquire the v17 documents. Download the four PE009-17 files (Introduction, Part I, Part II, Annexes) from the PIC/S publications page into the QMS reference library.
2. Run a clause-by-clause gap analysis. Compare the v17 text against your existing SOPs section by section. For non-sterile producers the gap is small and most edits are reference updates. For sterile producers the Annex 1 gap analysis is a major exercise: CCS framework, Quality Risk Management integration, aseptic process simulation, and barrier system requirements all need to be mapped.
3. Update the QMS reference layer. Site Master File, Quality Manual, and top-tier SOPs all need their PIC/S GMP reference updated to PE009-17 with the 1 September 2025 effective date. Change control captures the update.
4. Update lower-tier SOPs where v17 substantively changed. The deviation SOP, CAPA SOP, change control SOP, batch record templates, and self-inspection checklist are the typical candidates. Sterile producers also revise environmental monitoring SOPs, gowning procedures, and aseptic technique training.
5. Train staff on the changes. A documented training module with a competency check. Sign-in sheet and quiz results go in the training file. For non-sterile producers the module is short. For sterile producers it is a multi-hour session.
6. Confirm closure in the next self-inspection. The first self-inspection after the v17 effective date checks that the gap analysis was completed, the QMS updates were made, and training was delivered. This becomes the evidence file the next TGA inspector reads.

Frequently Asked Questions

When did PIC/S GMP v17 come into effect in Australia?

PE009-17 was published by PIC/S on 21 June 2023. The TGA adopted it with an effective date of 1 September 2025. From that date, every facility holding a TGA Licence to Manufacture Therapeutic Goods, including TGA-licensed cannabis manufacturers, is inspected against the v17 standard rather than v16.

What is the difference between PE009-16 and PE009-17?

The single substantive change is the revised Annex 1 on the Manufacture of Sterile Medicinal Products, which aligns PIC/S with the European Medicines Agency’s 2022 Annex 1 revision and introduces a formal Contamination Control Strategy requirement and sharper Quality Risk Management language. The rest of the Guide (Part I, Part II, Annex 7 for herbal products) carries forward with editorial cleanup but no new obligations. For non-sterile cannabis manufacturers the transition is mostly a documentation update.

Does PIC/S GMP v17 apply to cannabis cultivation?

Not directly. Cultivation (growing, cutting, drying) sits under PIC/S GMP Annex 7 for documentation purposes, but the TGA allows cultivation to proceed without a manufacturing licence provided the dried flower is supplied as starting material to a separately GMP-licensed facility. GMP applies the moment the material is transformed into a herbal preparation, which is usually at extraction or formulation.

Do I need a Contamination Control Strategy under v17?

Only if your facility performs sterile manufacturing. The CCS is a new requirement in the revised Annex 1 and applies to manufacturers of sterile medicinal products. Most Australian cannabis manufacturers produce non-sterile products (dried flower, oral oils, capsules, topicals) and do not need a formal CCS document. The Quality Risk Management principles in v17 still apply across all manufacturing.

How does PIC/S GMP v17 compare to Health Canada GPP or US FDA cGMP?

The three regimes converge on similar principles but rest on different legal instruments. PIC/S GMP is published by an international scheme and adopted by the TGA. Health Canada GPP is Canada’s own published standard under the Cannabis Regulations. US FDA cGMP is codified in 21 CFR Parts 210 and 211 and enforced directly by the FDA. A facility audit against one standard is not automatically recognised by the others.

What happens if my Australian cannabis facility is still operating to PE009-16?

After 1 September 2025, PE009-16 is no longer the TGA’s reference standard. A facility that has not updated its QMS, delivered staff training, or evidenced the transition in its self-inspection file is exposed to inspection observations. For non-sterile producers the catch-up is a few weeks of focused work. For sterile producers the Annex 1 catch-up is a multi-month exercise.

Get the Full Australian Compliance Guide

The complete PDF covers ODC licensing, TGO 93 testing limits, PIC/S GMP v17 transition, GACP cultivation, and quarterly reporting deadlines in one inspection-ready reference for Australian LPs and TGA-licensed manufacturers.

Download Free Australian Guide